Heart failure & cardiomyopathiesSecondary analysis
Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction – Results from the EMPULSE Trial
- Secondary analysis of the EMPULSE randomised trial
- subgroup analysis by left ventricular ejection fraction (LVEF)
Authors' conclusion
The clinical benefit of empagliflozin proved consistent across LVEF categories in the EMPULSE trial.
Study context
- Population
- Patients hospitalised for acute de novo or decompensated heart failure (HF), irrespective of LVEF; classified as HFrEF (LVEF ≤40%), HFmrEF (41–49%) or HFpEF (≥50%)523 with baseline data
- Participants
- 530 patients
- Comparison
- Empagliflozin vs placebo across LVEF categories
- Primary endpoint
- Hierarchical outcome of death, worsening HF events and quality of life, assessed by win ratio
- Follow-up
- 90 days
Primary result
As reported in the abstract
Clinical benefit (hierarchical composite of all-cause death, HF events (HFE) and KCCQ total symptom score) by LVEF category
Empagliflozin vs PlaceboWin ratio
LVEF ≤40% (HFrEF, n = 354)
1.35(95% CI 1.04–1.75)
LVEF 41-49% (HFmrEF, n = 54)
1.25(CI 0.66–2.37)
LVEF ≥50% (HFpEF, n = 115)
1.40(CI 0.87–2.23)
Secondary outcomes
Individual components of the hierarchical primary endpoint
- Results consistent across LVEF categories
Original publication
Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction – Results from the EMPULSE Trial. Eur J Heart Fail. Published 4 April 2024. doi:10.1002/ejhf.3218
Summarised from the published abstract; every number is checked against it